Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Back to all database documentation: Neurofibromatosis Research Tools Database: Documentation

Antibodies:

...

must pass schematic validation

In order to ensure a consistent nomenclature for antibody targets we request that you use the following nomenclature:

  • epitope should be formatted using the following style:

    • if phospho-specific, have the prefix “phospho-” followed by

    • gene symbol/protein symbol e.g. “NF2” followed by

    • if phospho-specific, should label the phospho-target in parentheses with the three-character amino acid (aa) abbreviation followed by the location e.g. “(Ser2515)” followed by

    • if mutation-specific, should label the protein variant using one-character aa abbreviation eg. “(G12V)” followed by

    • if available, aa location of target in parentheses in the format of (aa START-END) e.g. “(aa 100-150)” or “(aa 507-530 N-term)”

    • examples of valid epitopes:

      • NF1

      • phospho-NF1 (Ser2515)

      • KRAS (G12V)

      • NF1 (aa 100-150)

      • NF1 (aa 507-530 N-term)

If you have an epitope that for does not fit in this nomenclature, let us know (Contact Us ) and we’d be happy to work with you to extend the nomenclature to fit your needs.